RVLM Sympathetic Neurons

📖 Wiki Page

cell1262 wordssynced 2026-04-02

Rostral Ventrolateral Medulla Sympathetic Neurons in Neurodegeneration

...

Rostral Ventrolateral Medulla Sympathetic Neurons in Neurodegeneration

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">RVLM Sympathetic Neurons</th>
</tr>
<tr>
<td class="label">Feature</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Ventrolateral medulla, caudal to pons</td>
</tr>
<tr>
<td class="label">Boundaries</td>
<td>Inferior olive (dorsal), pyramids (medial)</td>
</tr>
<tr>
<td class="label">Cell groups</td>
<td>C1 adrenergic + non-catecholaminergic</td>
</tr>
<tr>
<td class="label">Projections</td>
<td>Ipsilateral IML of spinal cord</td>
</tr>
<tr>
<td class="label">Blood supply</td>
<td>Penetrating branches of vertebral/basilar</td>
</tr>
<tr>
<td class="label">System</td>
<td>Effect on RVLM</td>
</tr>
<tr>
<td class="label">Glutamate</td>
<td>Excitatory</td>
</tr>
<tr>
<td class="label">GABA</td>
<td>Inhibitory</td>
</tr>
<tr>
<td class="label">Glycine</td>
<td>Inhibitory</td>
</tr>
<tr>
<td class="label">Serotonin</td>
<td>Excitatory</td>
</tr>
<tr>
<td class="label">Angiotensin II</td>
<td>Excitatory</td>
</tr>
<tr>
<td class="label">[Acetylcholine](/entities/acetylcholine)</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Orthostatic hypotension</td>
<td>Sympathetic denervation</td>
</tr>
<tr>
<td class="label">Supine hypertension</td>
<td>Residual sympathetic activity</td>
</tr>
<tr>
<td class="label">Nocturnal polyuria</td>
<td>Loss of circadian ADH</td>
</tr>
<tr>
<td class="label">Anhidrosis</td>
<td>Sympathetic cholinergic loss</td>
</tr>
<tr>
<td class="label">Urinary symptoms</td>
<td>Bladder dysfunction</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Pathophysiology</td>
</tr>
<tr>
<td class="label">Orthostatic hypotension</td>
<td>Sympathetic denervation</td>
</tr>
<tr>
<td class="label">Cardiac denervation</td>
<td>Postganglionic loss</td>
</tr>
<tr>
<td class="label">Baroreflex impairment</td>
<td>Central integration failure</td>
</tr>
<tr>
<td class="label">Constipation</td>
<td>Enteric + central</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>PD</td>
</tr>
<tr>
<td class="label">OH severity</td>
<td>Mild-moderate</td>
</tr>
<tr>
<td class="label">Cardiac denervation</td>
<td>Postganglionic</td>
</tr>
<tr>
<td class="label">Levodopa effect</td>
<td>May improve</td>
</tr>
<tr>
<td class="label">Prognosis</td>
<td>Better</td>
</tr>
<tr>
<td class="label">Cardiac MIBG</td>
<td>Reduced</td>
</tr>
<tr>
<td class="label">Change</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">Reduced C1 neurons</td>
<td>↓ Sympathetic drive</td>
</tr>
<tr>
<td class="label">Decreased TH</td>
<td>↓ Catecholamine synthesis</td>
</tr>
<tr>
<td class="label">GABA dysregulation</td>
<td>Impaired baroreflex</td>
</tr>
<tr>
<td class="label">Glutamate excess</td>
<td>Excitotoxic damage</td>
</tr>
<tr>
<td class="label">Test</td>
<td>Parameter</td>
</tr>
<tr>
<td class="label">Tilt table</td>
<td>OH severity</td>
</tr>
<tr>
<td class="label">Valsalva</td>
<td>Baroreflex function</td>
</tr>
<tr>
<td class="label">Deep breathing</td>
<td>Heart rate variability</td>
</tr>
<tr>
<td class="label">QSART</td>
<td>Sudomotor function</td>
</tr>
<tr>
<td class="label">Plasma norepinephrine</td>
<td>Supine/standing</td>
</tr>
<tr>
<td class="label">Intervention</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Fludrocortisone</td>
<td>Volume expansion</td>
</tr>
<tr>
<td class="label">Midodrine</td>
<td>α1 agonist</td>
</tr>
<tr>
<td class="label">Droxidopa</td>
<td>NE precursor</td>
</tr>
<tr>
<td class="label">Pyridostigmine</td>
<td>Enhance ganglionic transmission</td>
</tr>
<tr>
<td class="label">Compression garments</td>
<td>Reduce venous pooling</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Atomoxetine</td>
<td>Presynaptic NE reuptake</td>
</tr>
<tr>
<td class="label">Ampreloxetine</td>
<td>NE transporter inhibition</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Sympathetic neuron support</td>
</tr>
<tr>
<td class="label">Stem cells</td>
<td>Neuron replacement</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Central (MSA)</td>
</tr>
<tr>
<td class="label">OH onset</td>
<td>Subacute</td>
</tr>
<tr>
<td class="label">Motor symptoms</td>
<td>Present</td>
</tr>
<tr>
<td class="label">Sweating</td>
<td>Reduced globally</td>
</tr>
<tr>
<td class="label">MIBG uptake</td>
<td>Preserved</td>
</tr>
<tr>
<td class="label">Progression</td>
<td>Rapid</td>
</tr>
</table>

Overview

The rostral ventrolateral medulla (RVLM) contains presympathetic [neurons](/entities/neurons) that are the primary source of excitatory drive to the spinal sympathetic preganglionic neurons. These neurons are critical for maintaining basal vasomotor tone, blood pressure homeostasis, and autonomic regulation. In neurodegenerative disorders, particularly multiple system atrophy (MSA) and [Parkinson disease](/diseases/parkinsons-disease) (PD), RVLM dysfunction contributes to severe autonomic manifestations including orthostatic hypotension, blood pressure fluctuations, and sudden death risk.

Mermaid diagram (expand to render)

RVLM Neuroanatomy

Anatomical Organization

The RVLM is located in the ventrolateral medullary reticular formation:

C1 Adrenergic Neurons

The C1 cell group within the RVLM is the primary source of bulbospinal catecholaminergic projections:

Neurotransmitters: Epinephrine, norepinephrine, glutamate
Synthesis enzymes: TH, DBH, PNMT
Markers: Tyrosine hydroxylase, phenylethanolamine N-methyltransferase
Firing pattern: Pacemaker-like spontaneous activity
Target: Intermediolateral cell column (IML) at T1-L2

Non-C1 Neurons

A substantial proportion of RVLM presympathetic neurons are non-catecholaminergic:

Primary transmitter: Glutamate (VGLUT2 expressing)
Peptide co-transmitters: Substance P, neurokinin B
Function: Baroreflex integration
Proportion: ~50% of presympathetic neurons

Physiological Functions

Vasomotor Tone Generation

RVLM neurons maintain basal sympathetic tone through:

Spontaneous pacemaker activity: Intrinsic firing at 1-5 Hz

Respiratory coupling: Phasic modulation with breathing

Baroreflex integration: Negative feedback regulation

Chemoreflex response: Hypoxia/hypercapnia activation

Baroreflex Circuit

Mermaid diagram (expand to render)

Neurotransmitter Systems

Role in Multiple System Atrophy

Autonomic Failure Mechanism

MSA is characterized by severe autonomic dysfunction driven by RVLM pathology:

Neuronal loss: Progressive C1 neuron degeneration
Gliosis: Reactive astrocytosis in RVLM
GCIs: Glial cytoplasmic inclusions with [α-synuclein](/proteins/alpha-synuclein)
Connectivity disruption: Loss of bulbospinal projections

Clinical Manifestations

Cardiovascular Instability

OH severity: Often >60 mmHg SBP drop on standing
Postprandial hypotension: Blood pooling in splanchnic circulation
Exercise intolerance: Blunted cardiac response
Sudden death: Arrhythmia, apnea risk

Role in Parkinson Disease

Autonomic Dysfunction Spectrum

PD autonomic features reflect varying RVLM involvement:

Comparison with MSA

Sudden Death Risk

RVLM dysfunction in PD/MSA increases mortality:

Cardiac arrhythmias: Autonomic imbalance

Central apnea: Respiratory center dysfunction

Blood pressure crises: Labile hypertension

Aspiration: Brainstem involvement

Molecular Pathophysiology

α-Synuclein Pathology

In MSA, glial cytoplasmic inclusions affect RVLM:

Oligodendroglial GCIs: α-Synuclein aggregates
Neuronal dysfunction: Secondary to glial pathology
Mitochondrial impairment: Oxidative stress
Excitotoxicity: Glutamate dysregulation

Neurotransmitter Changes

Inflammatory Mechanisms

Microglial activation: Neuroinflammation in RVLM
Cytokine elevation: IL-1β, TNF-α in brainstem
Complement activation: Membrane attack complex
Astrogliosis: Reactive astrocyte response

Clinical Assessment

Autonomic Testing

Neuroimaging

Cardiac MIBG: Postganglionic denervation in PD
Cardiac PET: Sympathetic innervation assessment
Brain MRI: Brainstem atrophy in MSA
fMRI: RVLM functional connectivity

Therapeutic Approaches

Orthostatic Hypotension Management

Non-Pharmacological Strategies

Fluid intake: 2-3L/day

Salt supplementation: 6-10g/day if tolerated

Elevated head of bed: Reduce nocturnal diuresis

Slow position changes: Avoid rapid standing

Avoid triggers: Heat, alcohol, large meals

Emerging Therapies

Differential Diagnosis

Central vs Peripheral Autonomic Failure

Brainstem Disorders Affecting RVLM

Lateral medullary syndrome: Wallenberg syndrome
Brainstem tumors: Compression/infiltration
Syringobulbia: Cavity extension
Multiple sclerosis: Brainstem plaques

Research Directions

Biomarker Development

Microneurography: Direct sympathetic recording
Heart rate variability: Autonomic function markers
Plasma biomarkers: [Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain
Imaging biomarkers: Brainstem volumetry

Pathogenic Mechanisms

α-Synuclein spreading: Prion-like propagation to RVLM

Neuroinflammation: Microglial activation cascade

Mitochondrial dysfunction: Energy failure in C1 neurons

Excitotoxicity: Glutamate-mediated damage

External Links

[Allen Brain Atlas](https://portal.brain-map.org/)
[BrainSpan Atlas](https://www.brainspan.org/)
[Human Cell Atlas](https://www.humancellatlas.org/)

References

benarroch2019, The clinical neurology of autonomic failure (2019)
coon2022, Sudden death in synucleinopathies: autonomic and sleep mechanisms (2022)
goldstein2006, Orthostatic hypotension as an early finding in Parkinson disease (2006)
guyenet2017, The C1 neurons of the RVLM: essential for the baroreflex and the sympathetic response to stress (2017)
kaufmann2014, Droxidopa for neurogenic orthostatic hypotension (2014)
low2008, Autonomic dysfunction in multiple system atrophy (2008)
orimo2006, Cardiac sympathetic denervation in Lewy body disease (2006)
schreihofer2013, The ventrolateral medulla and sympathetic regulation of arterial pressure (2013)

Pathway Diagram

The following diagram shows the key molecular relationships involving RVLM Sympathetic Neurons discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

RVLM Sympathetic Neurons

Rostral Ventrolateral Medulla Sympathetic Neurons in Neurodegeneration

Rostral Ventrolateral Medulla Sympathetic Neurons in Neurodegeneration

Overview

RVLM Neuroanatomy

Anatomical Organization

C1 Adrenergic Neurons

Non-C1 Neurons

Physiological Functions

Vasomotor Tone Generation

Baroreflex Circuit

Neurotransmitter Systems

Role in Multiple System Atrophy

Autonomic Failure Mechanism

Clinical Manifestations

Cardiovascular Instability

Role in Parkinson Disease

Autonomic Dysfunction Spectrum

Comparison with MSA

Sudden Death Risk

Molecular Pathophysiology

α-Synuclein Pathology

Neurotransmitter Changes

Inflammatory Mechanisms

Clinical Assessment

Autonomic Testing

Neuroimaging

Therapeutic Approaches

Orthostatic Hypotension Management

Non-Pharmacological Strategies

Emerging Therapies

Differential Diagnosis

Central vs Peripheral Autonomic Failure

Brainstem Disorders Affecting RVLM

Research Directions

Biomarker Development

Pathogenic Mechanisms

See Also

External Links

References

Pathway Diagram